Luisa Salter-Cid

Dr. Luisa Salter-Cid joined Flagship Pioneering in 2021 as Chief Scientific Officer of Pioneering Medicines. She is responsible for pioneering a portfolio of groundbreaking medicines sourced from the broad spectrum of scientific platforms within Flagship’s ecosystem of companies. She is also focused on building a research capability within Pioneering Medicines and providing strategic leadership and oversight to all research programs to ensure the development of innovative, efficient, and safe medicines that address significant patient needs.

Luisa is a highly respected scientist and drug discovery and development leader with more than 20 years of experience in the biotech and pharmaceutical industries and a strong track record of bringing programs to the clinic. Prior to her role at Pioneering Medicines, Luisa was Chief Scientific Officer at Gossamer Bio where she was responsible for building the company’s portfolio of immunology and immuno-oncology clinical and new discovery programs. Previously, she spent 13 years at Bristol Myers Squibb (BMS) where she was most recently Vice President and Head of Immunology, Small Molecule Immuno-Oncology, and Genomics Discovery. In this role, she oversaw several biology groups focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet needs in autoimmune diseases and cancer. During her time at BMS, she led teams that advanced more than 20 compounds into clinical development, including Deucravacitinib. Luisa was Chair of the Immunoscience Target Science Team and a core member of Early Development, Strategy and Licensing teams for both Immunology and Immuno-Oncology. Additionally, she was the scientific lead on several of BMS’ acquisitions and licensing deals and sat on multiple Joint Research Committees and Scientific Advisory Boards. Prior to joining BMS, Luisa was a Senior Project Leader at La Jolla Pharmaceuticals and held positions at Genset Corp and Johnson & Johnson.

Luisa is a member of the Scientific Advisory Board of Anaptys, Ambrx and Ventyx Bio and was previously on the SAB of Prometheus and the Board of Directors of Jounce Therapeutics. She has authored over 80 publications and patents and holds a Ph.D. in Immunology from the University of Miami.